Cargando…

Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning

AIMS: It has been suggested that mitochondrial reactive oxygen species (ROS), Akt and Erk1/2 and more recently the mitochondrial permeability transition pore (mPTP) may act as mediators of ischaemic preconditioning (IPC), although the actual interplay between these mediators is unclear. The aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hausenloy, Derek J., Lim, Shiang Y., Ong, Sang-Ging, Davidson, Sean M., Yellon, Derek M.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936122/
https://www.ncbi.nlm.nih.gov/pubmed/20400621
http://dx.doi.org/10.1093/cvr/cvq113
_version_ 1782186452362199040
author Hausenloy, Derek J.
Lim, Shiang Y.
Ong, Sang-Ging
Davidson, Sean M.
Yellon, Derek M.
author_facet Hausenloy, Derek J.
Lim, Shiang Y.
Ong, Sang-Ging
Davidson, Sean M.
Yellon, Derek M.
author_sort Hausenloy, Derek J.
collection PubMed
description AIMS: It has been suggested that mitochondrial reactive oxygen species (ROS), Akt and Erk1/2 and more recently the mitochondrial permeability transition pore (mPTP) may act as mediators of ischaemic preconditioning (IPC), although the actual interplay between these mediators is unclear. The aim of the present study is to determine whether the cyclophilin-D (CYPD) component of the mPTP is required by IPC to generate mitochondrial ROS and subsequently activate Akt and Erk1/2. METHODS AND RESULTS: Mice lacking CYPD (CYPD−/−) and B6Sv129 wild-type (WT) mice were used throughout. We have demonstrated that under basal conditions, non-pathological mPTP opening occurs (indicated by the percent reduction in mitochondrial calcein fluorescence). This effect was greater in WT cardiomyocytes compared with CYPD−/− ones (53 ± 2% WT vs. 17 ± 3% CYPD−/−; P < 0.01) and was augmented by hypoxic preconditioning (HPC) (70 ± 9% WT vs. 56 ± 1% CYPD−/−; P < 0.01). HPC reduced cell death following simulated ischaemia–reperfusion injury in WT (23.2 ± 3.5% HPC vs. 43.7 ± 3.2% WT; P < 0.05) but not CYPD−/− cardiomyocytes (19.6 ± 1.4% HPC vs. 24.4 ± 2.6% control; P > 0.05). HPC generated mitochondrial ROS in WT (four-fold increase; P < 0.05) but not CYPD−/− cardiomyocytes. HPC induced significant Akt phosphorylation in WT cardiomyocytes (two-fold increase; P < 0.05), an effect which was abrogated by ciclosporin-A (a CYPD inhibitor) and N-2-mercaptopropionyl glycine (a ROS scavenger). Finally, in vivo IPC of adult murine hearts resulted in significant phosphorylation of Akt and Erk1/2 in WT but not CYPD−/− hearts. CONCLUSION: The CYPD component of the mPTP is required by IPC to generate mitochondrial ROS and phosphorylate Akt and Erk1/2, major steps in the IPC signalling pathway.
format Text
id pubmed-2936122
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-29361222010-09-13 Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning Hausenloy, Derek J. Lim, Shiang Y. Ong, Sang-Ging Davidson, Sean M. Yellon, Derek M. Cardiovasc Res Original Articles: Focus on Mitochondria in Cardiac Disease AIMS: It has been suggested that mitochondrial reactive oxygen species (ROS), Akt and Erk1/2 and more recently the mitochondrial permeability transition pore (mPTP) may act as mediators of ischaemic preconditioning (IPC), although the actual interplay between these mediators is unclear. The aim of the present study is to determine whether the cyclophilin-D (CYPD) component of the mPTP is required by IPC to generate mitochondrial ROS and subsequently activate Akt and Erk1/2. METHODS AND RESULTS: Mice lacking CYPD (CYPD−/−) and B6Sv129 wild-type (WT) mice were used throughout. We have demonstrated that under basal conditions, non-pathological mPTP opening occurs (indicated by the percent reduction in mitochondrial calcein fluorescence). This effect was greater in WT cardiomyocytes compared with CYPD−/− ones (53 ± 2% WT vs. 17 ± 3% CYPD−/−; P < 0.01) and was augmented by hypoxic preconditioning (HPC) (70 ± 9% WT vs. 56 ± 1% CYPD−/−; P < 0.01). HPC reduced cell death following simulated ischaemia–reperfusion injury in WT (23.2 ± 3.5% HPC vs. 43.7 ± 3.2% WT; P < 0.05) but not CYPD−/− cardiomyocytes (19.6 ± 1.4% HPC vs. 24.4 ± 2.6% control; P > 0.05). HPC generated mitochondrial ROS in WT (four-fold increase; P < 0.05) but not CYPD−/− cardiomyocytes. HPC induced significant Akt phosphorylation in WT cardiomyocytes (two-fold increase; P < 0.05), an effect which was abrogated by ciclosporin-A (a CYPD inhibitor) and N-2-mercaptopropionyl glycine (a ROS scavenger). Finally, in vivo IPC of adult murine hearts resulted in significant phosphorylation of Akt and Erk1/2 in WT but not CYPD−/− hearts. CONCLUSION: The CYPD component of the mPTP is required by IPC to generate mitochondrial ROS and phosphorylate Akt and Erk1/2, major steps in the IPC signalling pathway. Oxford University Press 2010-10-01 2010-04-16 /pmc/articles/PMC2936122/ /pubmed/20400621 http://dx.doi.org/10.1093/cvr/cvq113 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org. http://creativecommons.org/licenses/by-nc/2.5/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.
spellingShingle Original Articles: Focus on Mitochondria in Cardiac Disease
Hausenloy, Derek J.
Lim, Shiang Y.
Ong, Sang-Ging
Davidson, Sean M.
Yellon, Derek M.
Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning
title Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning
title_full Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning
title_fullStr Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning
title_full_unstemmed Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning
title_short Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning
title_sort mitochondrial cyclophilin-d as a critical mediator of ischaemic preconditioning
topic Original Articles: Focus on Mitochondria in Cardiac Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936122/
https://www.ncbi.nlm.nih.gov/pubmed/20400621
http://dx.doi.org/10.1093/cvr/cvq113
work_keys_str_mv AT hausenloyderekj mitochondrialcyclophilindasacriticalmediatorofischaemicpreconditioning
AT limshiangy mitochondrialcyclophilindasacriticalmediatorofischaemicpreconditioning
AT ongsangging mitochondrialcyclophilindasacriticalmediatorofischaemicpreconditioning
AT davidsonseanm mitochondrialcyclophilindasacriticalmediatorofischaemicpreconditioning
AT yellonderekm mitochondrialcyclophilindasacriticalmediatorofischaemicpreconditioning